Rationale: Vascular endothelial growth factor (VEGF), a major proangiogenic agent, exerts its proangiogenic action by binding to VEGF receptor 2 (VEGFR2), the activity of which is regulated by direct interactions with other cell surface proteins, including integrin ␣ V ␤ 3 . However, how the interaction between VEGFR2 and integrin ␣ V ␤ 3 is regulated is not clear.
A ngiogenesis plays an important role in diverse developmental, physiological, and pathological processes. Angiogenesis is triggered by the interaction of proangiogenic growth factors and extracellular matrix with their receptors. Vascular endothelial growth factor (VEGF) is a major proangiogenic agent that regulates multiple key steps of angiogenesis. VEGF exerts its proangiogenic action by binding to VEGF receptor 2 (VEGFR2). The activity of VEGFR2 is regulated by direct interactions with other cell surface proteins, such as coreceptor neuropilins 1 and adhesion molecules, including VE-cadherin 2 and integrins. 3 Integrins, including integrin ␣ V ␤ 3 , are critically involved in angiogenesis and initiate signals that control cell migration, proliferation, and survival. 4 Receptors such as VEGFR2 and plateletderived growth factor (PDGF) receptor (PDGFR) interact with integrins, and these interactions exhibit synergistic effects and cooperatively regulate diverse intracellular signals that control key cell functions. 3, 5, 6 However, how the interaction between VEGFR2 and integrin ␣ V ␤ 3 through their extracellular regions is regulated is not known.
Nectins and nectin-like molecules (Necls) are immunoglobulinlike cell adhesion molecules that are essential for the formation of cell-cell adhesions, and these molecules regulate a variety of cellular functions, including cell polarization, differentiation, movement, proliferation, and survival. 7, 8 Necls comprise a family with 5 members, Necl-1 to -5, and among these, Necl-5 exhibits distinctive expression profiles. Necl-5 was originally identified as human poliovirus receptor (PVR), also termed CD155, 9, 10 and as rodent Tage4, which is overexpressed in rodent colon carcinoma. 11, 12 Necl-5 is expressed ubiquitously, but its expression level is extremely low in most adult organs in rodents. 13, 14 However, it becomes upregulated in the developing or regenerating liver 15, 16 and transformed cells. 17, 18 In NIH3T3 cells, Necl-5 forms a complex with integrin ␣ V ␤ 3 and PDGFR, and the formation of this complex enhances cell movement and proliferation. 19 However, the function of Necl-5 and its mode of action in vascular endothelial cells (ECs) have not been established.
Accumulating evidence regarding the crucial function of Necl-5 in NIH3T3 cells by interacting with integrin ␣ V ␤ 3 and PDGFR implies that endothelial Necl-5 regulates EC movement and proliferation, as well as angiogenesis. However, there is only 1 report in which the endothelial function of Necl-5 was investigated, and this paper shows that Necl-5 is localized at interendothelial cell junctions and regulates transendothelial migration of monocytes. 20 Importantly, the in vivo endothelial function of Necl-5 is not known. Thus, the roles of Necl-5 in EC movement and proliferation, critical features of angiogenesis, as well as angiogenesis in vivo remain to be determined.
Here we investigated the role of Necl-5 in the VEGFinduced angiogenesis. We observed that although Necl-5-knockout (KO) mice displayed no obvious defect in vascular development, recovery of blood flow after hindlimb ischemia and the VEGF-induced neovascularization in implanted Matrigel plugs were impaired in Necl-5-KO mice. Necl-5 regulated the VEGF-induced network formation, migration, proliferation and survival of cultured human ECs by finetuning of the VEGFR2-mediated signaling and controlling the interaction between VEGFR2 and integrin ␣ V ␤ 3 .
Methods

Antibodies, Plasmids, and Reagents
Rat antimouse Necl-5 monoclonal antibody (mAb) was prepared as described previously. 21 Rabbit antihuman Necl-5/PVR polyclonal Ab (pAb) (Abcam, Cambridge, UK), mouse antihuman Necl-5/ CD155 mAb (R&D Systems, Minneapolis, MN), mouse anti-PECAM-1 mAb (Dako, Glostrup, Denmark), isolectin B4-AF488 conjugates (Invitrogen, Carlsbad, CA), mouse anti-␣ smooth muscle actin (SMA) mAb, mouse anti-FLAG mAb, rabbit anti-FLAG pAb (Sigma-Aldrich, St. Louis, MO), rabbit anti-VEGFR2 pAb (Abcam and Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-VEGFR1 pAb, mouse antiactin mAb, rabbit anti-Rap1 pAb (Santa Cruz Biotechnology), mouse antiphospho-VEGFR2 (Y951) mAb, rabbit antiphospho-VEGFR2 (Y1175) mAb, rabbit antiphospho-Akt (Ser473) pAb, rabbit antiphospho-Akt (Thr308) pAb, mouse antiAkt mAb, mouse antiphospho-endothelial nitric oxide synthase (eNOS) (Ser1777) mAb, mouse anti-eNOS mAb, rabbit antiphospho-c-Src (Y416) pAb, rabbit anti-c-Src pAb, rabbit antiphospho-ERK1/2 pAb, rabbit anti-ERK pAb, rabbit antiphosphop38 pAb, rabbit anti-p38 pAb, rabbit anticaspase-3 mAb (Cell Signaling Technology, Beverly, MA), and mouse anti-integrin ␣v mAb (Millipore, Billerica, MA) were purchased from commercial sources. HRP-conjugated secondary Abs were purchased from GE Healthcare Bioscience (Little Chalfont, UK). Fluorophore (FITC and Cy3)-conjugated secondary Abs were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). We prepared pCAGIPuro-FLAG-Necl-5, pCAGIZeo-FLAG-Necl-5-⌬CP, and pCAGIZeo-FLAG-Necl-5-⌬EC as described. 22 The pCI-neo-VEGFR1/Flt1 was a kind gift from Dr. M. Hirashima (Kobe University). The pCI-neo-VEGFR2 was constructed using pBluescript-VEGFR2, a kind gift from Dr. M. Shibuya (Tokyo Medical and Dental University). Human recombinant VEGF and PDGF were purchased from PeproTech (Rocky Hill, NJ).
Immunohistochemistry
Mice were perfused with saline, followed by perfusion with 4% paraformaldehyde in PBS at physiological pressure through the beating heart. Mouse limbs were isolated and embedded in paraffin. Sections were stained with the indicated Abs, and the signals were visualized using diaminobenzidine (DAB) (Dako).
Immunofluorescence Microscopy
HUVECs were fixed with 4% paraformaldehyde in PBS, incubated with 1% BSA in PBS, then incubated with Blocking One (Nacalai) in PBS. 23 The samples were stained with the indicated Abs and then with appropriate fluorophore-conjugated secondary Abs. The fluorescent signals were visualized with a confocal laser scanning microscope (LSM700, Carl Zeiss, Oberkochen, Germany).
Animal Experiments
Animal experiments were approved by the Institutional Animal Care and Use Committee and carried out according to the Kobe University Animal Experimental Regulations. Twelve-week-old male Necl-5-KO mice (50%, 129/Sv; 25%, C57BL/6; 25%, DBA) 24 or agematched wild-type (WT) mice of the same background were used. The mouse hindlimb ischemia, 23 the Matrigel plug assays, 23 Western blotting and coimmunoprecipitation assays were performed by standard methods, as described previously. 23 The activity of Rap1 was measured by a pull-down assay using GST-RalGDS-RBD, as described previously. 23
Capillary-Like Network Formation on Matrigel
Capillary-like network formation on Matrigel was investigated as described previously. 23
Boyden Chamber Assay
Cell migration was investigated using the Boyden chamber assay as described previously. 23 
Directional Stimulation
To generate a concentration gradient of VEGF and PDGF, we used a -slide VI flow (uncoated; Ibidi, München, Germany). 23
Cell Adhesion Assay
HUVECs serum-starved in EBM-2 plus 0.1% FBS overnight were suspended in EBM-2 plus 0.1% BSA at a density of 2ϫ10 5 cells/mL. One hundred microliters of cell suspension were applied to each well of precoated 96-well plates and then incubated for 1 hour at 37°C. After incubation, unattached cell and residual buffer were removed. Cells were stained with crystal violet and lysed in 100 L of 10% acetic acid. The optical density at 595 nm of the crystal violet solutions was measured.
Cell Proliferation
HUVECs (3ϫ10 4 cells per well) were plated onto 24-well plates precoated with vitronectin and cultured in EGM-2 at 37°C in 5% CO 2 . The number of cells was quantified using cell caulers according to manufacturer's instructions.
BrdU Assay
DNA synthesis was measured by BrdU incorporation as described previously. 19 
Apoptosis Assay
Early and late apoptosis were investigated using annexin V staining and the TUNEL assay, respectively, as described previously. 23 An expanded Methods section is available in the online-only Data Supplement.
Results
Expression of Necl-5 in Capillary ECs in Mouse Hindlimbs
We first examined the expression of Necl-5 in vascular ECs. It has been reported that Necl-5 is expressed at very low levels and the cell surface expression of Necl-5 is undetectable by immunohistochemistry in most adult organs in rodents. 13, 14 However, we observed positive staining for Necl-5 using an antimouse Necl-5 mAb 21 in mouse hindlimb capillary endothelium that was positive for PECAM-1 staining (Online Figure IA) . The immunofluorescence signal for Necl-5 was colocalized with that for isolectin B4 in capillary endothelium. In contrast, the signal for Necl-5 was very faint in ␣SMA-positive arteries (Online Figure IB) . Thus, Necl-5 was predominantly expressed in capillary ECs in mouse hindlimbs. The signal for Necl-5 was observed in ECs in brain microvessels, but not in the coronary artery or aorta (Online Figure IC) . Therefore, the expression of Necl-5 in ECs is not ubiquitous in the whole body. 
Impairment of Blood Flow Recovery After Hindlimb Ischemia and the VEGF-Induced Neovascularization in Matrigel Plugs in Necl-5-KO Mice
Necl-5-KO mice showed normal vascular development, gross growth, and breeding. 24 Necl-5-KO mice displayed the absence of Necl-5 staining in the hindlimbs (Online Figure II) . First, we explored the role of Necl-5 in blood flow recovery after hindlimb ischemia. WT and Necl-5-KO male mice were subjected to the femoral artery ligation, and the blood flow in the ischemic and nonischemic limbs was compared before and 0 (post), 1, 3, 7, 14, and 28 days after surgery ( Figure  1A ). The ratio of left-to-right leg blood flow was 1 before surgery, while the blood flow similarly dropped to nearly 20% after surgery in WT and Necl-5-KO mice. The blood flow in the ischemic limbs gradually recovered in both WT and Necl-5-KO mice, whereas the recovery was slightly, but significantly, impaired in Necl-5-KO mice in comparison with WT mice at 7, 14, and 28 days after surgery ( Figure 1A ). In general, arteriogenesis significantly contributes to blood flow recovery in ischemic hindlimbs. Therefore, we performed the Matrigel plug assay to examine the effect of genetic deficiency of Necl-5 in angiogenesis. The length of newly formed vessels in the VEGF-containing Matrigel plugs was significantly lower in Necl-5-KO mice than in WT mice ( Figure 1B) . Thus, the deficiency of Necl-5 impaired recovery of blood flow after hindlimb ischemia and the VEGFinduced neovascularization in mice.
Upregulation of Necl-5 After Hindlimb Ischemia
We wondered why Necl-5-KO mice exhibited impaired recovery of blood flow after hindlimb ischemia, although the expression of Necl-5 is very low and Necl-5-KO mice displayed no obvious defect in vascular development. Because hypoxia is known to increase the expression of VEGF, we hypothesized that there might be an association between the hypoxic environment and the expression of Necl-5. The expression of Necl-5 mRNA was significantly upregulated 1 day after surgery and was gradually decreased (Figure 2A ). The upregulation of Necl-5 protein expression was confirmed by Western blotting ( Figure 2B ). The signal for Necl-5 was observed only at capillary endothelium in the ischemic hindlimbs (data not shown). However, because not only ischemia but also inflammation is involved in hindlimb ischemia, the expression levels of Necl-5 in mice exposed to hypoxia were analyzed. The expression levels of Necl-5 mRNA were unchanged by exposure to hypoxia ( Figure  2C ), although the expression of Necl-5 in HUVECs was significantly increased after 24 or 48 hours of hypoxic culture ( Figure 2D ). Therefore, it is likely that inflammation plays a role in the upregulation of Necl-5 after hindlimb ischemia.
Impairment of Capillary-Like Network Formation and Migration by Knockdown of Necl-5
We investigated the role of Necl-5 in the VEGF-induced angiogenic responses in vitro. To this end, we chose to use the gene knockdown strategy because primary cultured mouse lung ECs from Necl-5-KO mice did not proliferate well and could not be used for the experiments. Seventy-two hours after transfection, 2 different siRNAs for Necl-5, but not control siRNA, effectively (nearly 90%) knocked down the expression of Necl-5 in HUVECs ( Figure 3A and Online Figure IV) . We compared capillary-like network formation on Matrigel between control and Necl-5 siRNA-transfected HUVECs. Capillary-like network formation on Matrigel in the presence of VEGF was significantly retarded in Necl-5-knockdown HUVECs in comparison with control HUVECs ( Figure 3B) .
We then assessed cell migration by the Boyden chamber assay. The number of migrated cells was significantly decreased by knockdown of Necl-5 irrespective of matrices ( Figure 3C ). Cell adhesion to fibronectin, laminin, and vitronectin was increased by knockdown of Necl-5 (Online Figure V) . Moving cells form protrusive structures, such as filopodia and lamellipodia, and peripheral ruffles at the leading edge. 27, 28 We showed previously that Necl-5 played a key role in the formation of leading edge structures during migration of NIH3T3 cells. 29 We therefore examined whether Necl-5 was involved in the formation of leading-edge structures of moving HUVECs. When the cells were directionally stimulated with VEGF using -slide VI flow, most cells were polarized, formed protrusions, and migrated toward higher concentrations of VEGF (Online Figure VIA) . We observed the colocalization of Necl-5 with integrin ␣ V or VEGFR2 at the leading edge ( Figure 3D and data not shown). However, the VEGF-induced formation of the leading edge and colocalization of Necl-5 with integrin ␣ V or VEGFR2 at peripheral membranes were abrogated in Necl-5-knockdown HUVECs. These results indicate a critical role of Necl-5 in the VEGF-induced formation of the leading edge in HUVECs. Furthermore, the PDGF-induced cell migration and formation of the leading edge were also inhibited by knockdown of Necl-5 ( Figure 3C and Online Figure VIB) . Thus, Necl-5 regulates capillary-like network formation and migration.
Requirement of Necl-5 for EC Survival
When we studied the in vitro experiments in which the effect of knockdown of Necl-5 was analyzed as described above, we noticed that the number of HUVECs after the transfection of Necl-5 siRNAs was significantly less than that of the control cells ( Figure 4A ). We observed no increase, but rather a slight decrease in the number of Necl-5-knockdown HUVECs during the period of cell culture. Although the percentage of BrdU-incorporated cells was decreased by knockdown of Necl-5 regardless of the presence or absence of VEGF treatment, BrdU incorporation was increased by VEGF in Necl-5-knockdown HUVECs ( Figure 4B ), indicating that these cells indeed proliferated in response to VEGF. These observations led us to determine the role of Necl-5 in cell survival. Apoptosis induced by serum deprivation was significantly enhanced by knockdown of Necl-5 ( Figure 4C ). Apoptosis occurred significantly in Necl-5-knockdown HUVECs even in the presence of VEGF or serum. Similar results were obtained by TUNEL assays (Figure 4D ). Even in the presence of serum, apoptosis significantly occurred 48 to 96 hours after the transfection of Necl-5 siRNAs (Online Figure VII) , which coincided with silencing of Necl-5 (Online Figure IV) . These results indicate that Necl-5 is indispensable for survival of HUVECs.
Regulation of the Interaction Between VEGFR2 and Integrin ␣ V ␤ 3 by Necl-5
We previously showed that Necl-5 interacted with PDGFR in NIH3T3 cells. 22 We examined whether Necl-5 interacted with VEGFR1 or VEGFR2 using a coimmunoprecipitation assay. FLAG-Necl-5 and either VEGFR1 or VEGFR2 were expressed in HEK293 cells, and then either VEGFR1 or VEGFR2 was immunoprecipitated with the anti-VEGFR1 or anti-VEGFR2 pAbs. FLAG-Necl-5 was coimmunoprecipitated with VEGFR2, but not with VEGFR1 ( Figure 5A ). VEGFR2 and either full-length FLAG-Necl-5 or FLAGNecl-5 mutants whose extracellular or cytoplasmic region was deleted (FLAG-Necl-5-⌬EC or FLAG-Necl-5-⌬CP, respectively) were expressed in HEK293 cells. When VEGFR2 was immunoprecipitated with the anti-VEGFR2 pAb, FLAGNecl-5 and FLAG-Necl-5-⌬CP were coimmunoprecipitated, whereas FLAG-Necl-5-⌬EC was not ( Figure 5B ). Conversely, when FLAG-Necl-5 mutants was immunoprecipitated with the anti-FLAG mAb, VEGFR2 was coimmunoprecipitated with FLAG-Necl-5 and FLAG-Necl-5-⌬CP, but not with FLAG-Necl-5-⌬EC ( Figure 5C ). These results indicate that the extracellular region of Necl-5 interacts with VEGFR2.
We examined the effect of knockdown of Necl-5 on the interaction between VEGFR2 and integrin ␣ V ␤ 3 . VEGFR2 interacts with integrin ␣ V ␤ 3 , and this interaction regulates the activation of downstream phosphatidylinositol 3-kinase (PI3K) that controls the VEGF-promoted cell proliferation and migration. 3 When VEGFR2 was immunoprecipitated with the anti-VEGFR2 pAb, integrin ␣ V ␤ 3 was coimmunoprecipitated with VEGFR2, and VEGF increased the amount of integrin ␣ V ␤ 3 coimmunoprecipitated with VEGFR2 (Figure 5D ). This finding indicates that VEGF increased the interaction between VEGFR2 and integrin ␣ V ␤ 3 . However, this interaction was attenuated by knockdown of Necl-5 regardless of the presence or absence of VEGF treatment. These results indicate that Necl-5 regulates the interaction between VEGFR2 and integrin ␣ V ␤ 3 . 
Enhancement of the VEGF-Promoted Proangiogenic and Survival Signaling Pathways by Necl-5
To further define a mechanism by which Necl-5 regulates the VEGF signaling and survival of ECs, we examined the effect of knockdown of Necl-5 on the phosphorylation of VEGFR2, c-Src, Akt, eNOS, ERK, and p38 ( Figure 6A ). The phosphorylation of VEGFR2 at Y951, Akt, and eNOS was increased by VEGF treatment, and the VEGF-induced phosphorylation of these proteins was significantly decreased by knockdown of Necl-5 ( Figure 6A ). However, knockdown of Necl-5 did not affect the VEGF-induced phosphorylation of VEGFR2 at Y1175, c-Src, ERK, or p38 ( Figure 6A ). The Akt signaling pathway not only mediates the VEGF-induced proangiogenic response, but also regulates cell survival. 30 To clarify the mechanism of the enhanced apoptosis by knockdown of Necl-5, we analyzed the effect of knockdown of Necl-5 on the cleavage of caspase-3, a marker for apoptosis. The serum deprivation-induced increase in the amount of cleaved caspase-3 was enhanced by knockdown of Necl-5 ( Figure  6B ). We recently reported that Rap1 regulates the VEGFinduced Akt signaling pathway. 23 Therefore, it is possible that Necl-5 regulates the VEGF-induced Akt signaling pathway through Rap1. To determine this possibility, we examined the effect of knockdown of Necl-5 on the activation of Rap1. The VEGF-induced activation of Rap1 was inhibited by knockdown of Necl-5 ( Figure 6C ), suggesting that Necl-5 regulates the Akt signaling pathway through Rap1. Taken together, these results indicate that Necl-5 regulates the VEGF-induced activation of proangiogenic and survival signaling pathways.
Discussion
In the present study, we showed that Necl-5 was dispensable for vascular development but regulated blood flow recovery Lysates of the cells were subjected to a coimmunoprecipitation assay using anti-FLAG mAb and the samples were assessed by Western blotting using the indicated Abs. B and C, Interaction of Necl-5 with VEGFR2. HEK293 cells were transfected with VEGFR2 and FLAG-tagged Necl-5, Necl-5-⌬CP, or Necl-5-⌬EC. Lysates of the cells were subjected to a coimmunoprecipitation assay using anti-VEGFR2 pAb (B) or anti-FLAG mAb (C). The samples were assessed by Western blotting using anti-FLAG mAb or VEGFR2 pAb. Asterisks indicate the bands of FLAG-tagged Necl-5. D, Inhibition of the interaction of integrin ␣ V ␤ 3 with VEGFR2 by knockdown of Necl-5. HUVECs transfected with control or Necl-5 siRNAs were cultured in the presence or absence of VEGF for 5 minutes. Immunoprecipitates with anti-VEGFR2 pAb were subjected to Western blotting using the indicated Abs.
after hindlimb ischemia. The reason why Necl-5-KO mice showed normal vascular development is unknown, but this inconsistency can be explained by the facts that (1) the expression of Necl-5 in ECs was not ubiquitously distributed in the whole body; (2) the expression of Necl-5 in ECs was upregulated by hindlimb ischemia; and (3) other molecules compensate the absence of Necl-5. Besides Necl-5-KO mice, several KO mice were reported to show normal development but impaired postnatal angiogenesis and vascular remodeling. For example, deficiency of the VEGF homolog placental growth factor 31 and Akt 32 in mice did not affect embryonic vascular development, but showed impaired postnatal angiogenesis following ischemia. It remains unknown why the absence of these genes are not compensated in ischemiainduced angiogenesis in adulthood, although they are compensated during development.
We demonstrated here that Necl-5 was upregulated by hindlimb ischemia, but unchanged by hypoxia in vivo. Because both hypoxia and inflammation are involved in hindlimb ischemia, inflammation plays a major role in the upregulation of Necl-5. We found that Necl-5 was upregulated by treatment of HUVECs with proinflammatory cytokines including tissue necrosis factor-␣ (unpublished observation), although a mechanism needs to be clarified. Because angiogenesis is a critical part of inflammation, Necl-5 may serve as a molecular link between inflammation and angiogenesis as VEGF does. In addition, we showed that blood flow recovery after hindlimb ischemia was impaired in Necl-5-KO mice. It is likely that the Necl-5 plays a role in inflammation that plays a role in blood flow recovery because it was reported that Necl-5 is involved in transendothelial migration of monocytes, 20 although the role of Necl-5 in arteriogenesis and mobilization of inflammatory cells and bone marrow-derived cells needs to be elucidated.
We showed here that knockdown of Necl-5 reduced cell migration, but increased cell adhesion to various matrices including vitronectin and fibronectin, ligands for integrin ␣ V ␤ 3 . These results indicate that knockdown of Necl-5 enhanced the adhesive activity of integrin ␣ V ␤ 3 to its ligand. We recently reported that Rap1 regulated the VEGF-induced migration of HUVECs 23 and showed here that the VEGFinduced activation of Rap1 was inhibited by knockdown of Necl-5. Thus, decreased activation of the Rap1-Akt signaling pathway was likely to play a role in reduced cell migration in Necl-5-knockdown HUVECs. However, mechanisms of how Necl-5 regulates Rap1 activity remain to be elucidated.
In contrast to decreased activation of the Rap1-Akt signaling pathway, the ERK signaling pathway was not defective in Necl-5-knockdown HUVECs. This finding is consistent with the result that the phosphorylation of VEGFR2 at Y1175 was not affected by knockdown of Necl-5, because this site is known to be associated with the activation of the phospholipase C␥-ERK signaling pathway. 33 Recent studies have demonstrated that tyrosine kinase receptors including VEGFR2 initiate their signals not from the plasma membrane but rather from endosomal compartments 34 and thus disruption of endocytosis can affect receptor signaling. 35 It was reported that the activation of Y1175 VEGFR2-ERK signaling pathway was critically involved in VEGFR2 endocytosis. 36 Therefore, it is unlikely that Necl-5 is involved in VEGFR2 endocytosis. Because VEGFR2 endocytosis regulates arterial morphogenesis, normal arterial development in Necl-5-KO mice appears to be consistent with the activation of Y1175 VEGFR2-ERK signaling pathway in Necl-5-knockdown HUVECs.
Besides VEGFR2, integrin ␣ V ␤ 3 interacts with other growth factor receptors, such as PDGFR, 37 FGF receptor, 38 and insulin-like growth factor receptor. 39 These receptors have the potential for promoting angiogenesis. 40, 41 We have previously reported that Necl-5 interacts with PDGFR and integrin ␣ V ␤ 3 in NIH3T3 cells. 22, 29 We therefore examined the effect of knockdown of Necl-5 on the PDGF-induced migration and formation of the leading edge. We found that they were inhibited by knockdown of Necl-5. Thus, the involvement of Necl-5 in angiogenesis was not restricted to the action of VEGF, although further studies are required to examine whether Necl-5 is involved in angiogenesis mediated by other growth factor receptors that do not interact with integrin ␣ V ␤ 3 .
It is well known that VEGF exerts its angiogenic activity by binding to VEGFR2. In addition to VEGFR2, VEGFR1 also plays a role in the action of VEGF. We therefore examined the interaction of Necl-5 with these receptors. We showed here that Necl-5 interacted with VEGFR2, but not VEGFR1. The result is consistent with the observations that integrin ␣ V ␤ 3 , a critical regulator of VEGF-induced angiogenesis, interacts with VEGFR2, but not with VEGFR1 42 and that the antiapoptotic effect of VEGF is dependent on VEGFR2 but independent of VEGFR1. 43 We showed here that the extracellular region of Necl-5 interacted with VEGFR2. This result is consistent with the fact that the extracellular region of Necl-5 interacted with PDGFR. 22 We demonstrated here that Necl-5 regulated the VEGFinduced proangiogenic activities by controlling the Rap1-Akt signaling pathway through the interaction between VEGFR2 and integrin ␣ V ␤ 3 . How did Necl-5 regulate the interaction between VEGFR2 and integrin ␣ V ␤ 3 ? With regard to the cross-talk between VEGFR2 and integrin ␣ V ␤ 3 , a previous study demonstrated a critical role of c-Src. 6 VEGF stimulates the recruitment and activation of c-Src, and activated c-Src subsequently induces tyrosine phosphorylation of integrin ␤ 3 , which in turn stimulates the activity of VEGFR2 and its downstream signaling. 6 However, knockdown of Necl-5 in HUVECs did not inhibit the VEGF-induced phosphorylation of c-Src. Thus, Necl-5 extracellularly regulates the cross-talk between VEGFR2 and integrin ␣ V ␤ 3 independently of c-Src.
We found that Necl-5 regulated the VEGF-induced angiogenesis and exerted key functions in fine-tuning VEGFR2-mediated signaling. However, the clinical relevance of Necl-5 to the pathogenesis of various angiogenesis-related diseasessuch as atherosclerosis, diabetic retinopathy, and rheumatoid arthritis-is not known. Although the linkage between Ala 67 (GCG)-ϾThr (ACG) SNP in exon2 of Necl-5 gene and motor neuron disease or type 1 diabetes was reported, 44, 45 no reports show a linkage between cardiovascular diseases and SNP in Necl-5. This may be explained by the finding that Necl-5 was not expressed in coronary artery. The expression level of Necl-5 is very low in normal tissues and organs, but becomes upregulated in cancer. 11, 12, 17, 18 Indeed, inactivating Necl-5 by RNAi or interfering antibody inhibits cell proliferation and migration, as well as cancer metastasis. 19, 46 Although future studies are necessary to clarify whether Necl-5 is involved in tumor angiogenesis, Necl-5 may be a promising target molecule for cancer therapy because of its antiproliferative, anti-invasive, and antimetastatic properties, as well as the antiangiogenic effect of Necl-5 inactivation. Moreover, our results suggest that Necl-5 may be a novel target for the treatment of vascular diseases including peripheral artery diseases. Thus, pharmacological manipulation of Necl-5 may represent a novel therapeutic strategy in patients with angiogenesis-related disorders.
